Alberto Oddo

Alberto Oddo

Auto-generated profile, based on publicly available information

Alberto Oddo

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2016
Verified
Book Chapter
Closed access
PDF file
AOAlberto Oddo
Alberto Oddo
PHPaul Robert Hansen
Paul Robert Hansen

1 January 2015
Verified
Book Chapter
Closed access
PHPaul Robert Hansen
Paul Robert Hansen
AOAlberto Oddo
Alberto Oddo

1 January 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
AOAlberto Oddo
Alberto Oddo
TTThomas Thomsen
Thomas Thomsen
SKSusanne Kjelstrup
Susanne Kjelstrup
CGCiara Gorey
Ciara Gorey
HFHenrik Franzyk
Henrik Franzyk
PHPaul Robert Hansen
Paul Robert Hansen
Multiple strains of Acinetobacter baumannii have developed multidrug resistance (MDR), leaving colistin as the only effective treatment. The cecropin-α–melittin hybrid BP100 (KKLFKKILKYL-NH 2 ) and its analogs have previously shown activity against a wide array of plant and human pathogens. In this study, we investigated the in vitro antibacterial activities of 18 BP100 analogs (four known and 14 new) against the MDR A. baumannii strain ATCC BAA-1605, as well as against a number of other clinically relevant human pathogens. Selected peptides were further evaluated against strains of A. baumannii that acquired resistance to colistin due to mutations of the lpxC , lpxD , pmrA , and pmrB genes. The novel analogue BP214 showed antimicrobial activity at 1 to 2 μM and a hemolytic 50% effective concentration (EC 50 ) of >150 μM. The lower activity of its enantiomer suggests a dual, specific and nonspecific mode of action. Interestingly, colistin behaved antagonistically to BP214 when pmrAB and lpxC mutants were challenged.

19 July 2013 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MLMarius Löppenberg
Marius Löppenberg
HMHannes Müller
Hannes Müller
CPCarla Pulina
Carla Pulina
AOAlberto Oddo
Alberto Oddo
MTMark Teese
Mark Teese
Ralph HollRalph Holl
Ralph Holl
Inhibitors of the UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase (LpxC) represent promising candidates for the development of antibiotics possessing a so far unexploited mechanism of action. In a chiral pool synthesis, starting from the D-mannose derived mannonolactone 4, conformationally constrained C-glycosidic as well as open chained hydroxamic acids with a defined stereochemistry were prepared. Diversity was introduced by performing C–C coupling reactions like the Sonogashira and Suzuki cross-coupling reactions. The biological evaluation of the synthesized compounds revealed that in the case of the C-glycosides a long, linear and rigid hydrophobic side chain is required for antibiotic activity against E. coli. The open chain derivatives show higher biological activity than the conformationally constrained C-glycosides. The morpholinomethyl substituted open chain derivative 43, being the most potent compound presented in this paper, inhibits LpxC with a Ki value of 0.35 μM and represents a promising lead structure.

6 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IGInes Greco
Ines Greco
AEAgnete Plahn Emborg
Agnete Plahn Emborg
BJBimal Jana
Bimal Jana
NMNatalia Molchanova
Natalia Molchanova
AOAlberto Oddo
Alberto Oddo
PHPaul Robert Hansen
Paul Robert Hansen
Integumentary infections like pyoderma represent the main reason for antimicrobial prescription in dogs. Staphylococcus pseudintermedius and Pseudomonas aeruginosa are frequently identified in these infections, and both bacteria are challenging to combat due to resistance. To avoid use of important human antibiotics for treatment of animal infections there is a pressing need for novel narrow-spectrum antimicrobial agents in veterinary medicine. Herein, we characterize the in vitro activity of the novel peptide-peptoid hybrid B1 against canine isolates of S. pseudintermedius and P. aeruginosa. B1 showed potent minimum inhibitory concentrations (MICs) against canine S. pseudintermedius and P. aeruginosa isolates as well rapid killing kinetics. B1 was found to disrupt the membrane integrity and affect cell-wall synthesis in methicillin-resistant S. pseudintermedius (MRSP). We generated 28 analogues of B1, showing comparable haemolysis and MICs against MRSP and P. aeruginosa. The most active analogues (23, 26) and B1 were tested against a collection of clinical isolates from canine, of which only B1 showed potent activity. Our best compound 26, displayed activity against P. aeruginosa and S. pseudintermedius, but not the closely related S. aureus. This work shows that design of target-specific veterinary antimicrobial agents is possible, even species within a genus, and deserves further exploration.